Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 9/20 | 0.56 |
| ▸ | PPIB | P23284 | 6/20 | 0.56 |
| ▸ | PPIG | Q13427 | 5/20 | 0.56 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832198 | 0.86 | NAMPT (0.45) | PPIDPPIBPPIGEPHX2EPHX1 | |
| SCHEMBL14575947 | 0.79 | PPIB (0.68) | PPIDPPIBPPIGPPIAEPHX2 | |
| SCHEMBL12643832 | 0.77 | PPIB (0.53) | PPIDPPIBPPIGPPIAEPHX2 | |
| SCHEMBL12643755 | 0.76 | SMN1; SMN2 (0.68) | PPIDPPIBPPIGPPIAEPHX2 | |
| SCHEMBL12643846 | 0.76 | PPIB (0.59) | PPIDPPIBPPIGPPIAEPHX2 | |
| SCHEMBL15832160 | 0.74 | PPIB (0.44) | PPIDPPIBPPIGALDH1A1L3MBTL1 | |
| SCHEMBL14576864 | 0.74 | PPIB (0.63) | PPIDPPIBPPIGPPIAEPHX2 | |
| SCHEMBL12643850 | 0.73 | EPHX1 (0.66) | PPIDPPIBPPIGPPIAEPHX2 | |
| Aniline SCHEMBL27840986 | 0.72 | PPIB (0.60) | PPIDPPIBPPIGPPIAEPHX2 | |
| SCHEMBL12643824 | 0.72 | PPID (1.00) | PPIDPPIBPPIGPPIAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | PPID 73/4885PPIB 51/4885PPIG 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.